Sponsor:
Neonc Technologies, Inc.
Code:
NCT06047379
Conditions
Diffuse Astrocytoma, IDH-Mutant
Glioblastoma, IDH-wildtype
Brain Metastases, Adult
Cervical Cancer
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NEO212 Oral Capsule
Ipilimumab
Pembrolizumab
Nivolumab
Regorafenib
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by Neonc Technologies, Inc. on 2024-10-16.